AMGEVITA SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

ADALIMUMAB

Pieejams no:

AMGEN CANADA INC

ATĶ kods:

L04AB04

SNN (starptautisko nepatentēto nosaukumu):

ADALIMUMAB

Deva:

50MG

Zāļu forma:

SOLUTION

Kompozīcija:

ADALIMUMAB 50MG

Ievadīšanas:

SUBCUTANEOUS

Vienības iepakojumā:

0.8ML

Receptes veids:

Prescription

Ārstniecības joma:

DISEASE-MODIFYING ANTIRHEUMATIC AGENTS

Produktu pārskats:

Active ingredient group (AIG) number: 0150364003; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2020-11-04

Produkta apraksts

AMGEVITA
®
(adalimumab) Product Monograph
Page 1 of 169
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
AMGEVITA
®
adalimumab injection
20 mg in 0.4 mL sterile solution (50 mg/mL), prefilled syringe for
subcutaneous injection
40 mg in 0.8 mL sterile solution (50 mg/mL), prefilled syringe for
subcutaneous injection
40 mg in 0.8 mL sterile solution (50 mg/mL), prefilled SureClick
®
autoinjector for subcutaneous
injection
Professed Standard
Biologic Response Modifier
AMGEVITA (ADALIMUMAB INJECTION) TREATMENT SHOULD BE INITIATED AND
SUPERVISED BY
SPECIALIST PHYSICIANS EXPERIENCED IN THE DIAGNOSIS AND TREATMENT OF
RHEUMATOID ARTHRITIS,
POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS, PSORIATIC ARTHRITIS,
ANKYLOSING SPONDYLITIS, ADULT
AND PEDIATRIC (13 TO 17 YEARS OF AGE WEIGHING ≥ 40 KG) CROHN’S
DISEASE, ADULT AND
PEDIATRIC (5 TO 17 YEARS OF AGE) ULCERATIVE COLITIS, ADULT AND
ADOLESCENT (12 TO 17 YEARS OF
AGE WEIGHING ≥ 30 KG) HIDRADENITIS SUPPURATIVA, PSORIASIS OR ADULT
AND PEDIATRIC UVEITIS,
AND FAMILIAR WITH THE AMGEVITA EFFICACY AND SAFETY PROFILE.
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, ON L5N 0A4
Date of Initial Approval:
04 November, 2020
Submission Control No: 256159
Date of Revision:
09 September, 2022

2020-2022 Amgen Canada Inc., all rights reserved.
AMGEVITA
®
(adalimumab) Product Monograph
Page 2 of 169
RECENT MAJOR LABEL CHANGES
1 Indications
XX/XXXX
4 Dosage and Administration
07/2021
4 Dosage and Administration
XX/XXXX
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION..............................................................
4
1
INDICATIONS..............................................................................................................
4
1.1
Pediatrics
............................................................................................................
6
1.2
Geriatrics.............................................................................................................
6
2
CONTRAINDICATIONS
............................